Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE38.7050
- TODAY'S CHANGE (%)0.6350 (1.6680%)
- Bid / Lots38.6400/ 2
- Ask / Lots38.7600/ 4
- Open / Previous Close38.5400 / 38.0700
- Day Range
- 52 Week Range
- Volume110,896
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 4367 | 37.88 |
| 09:34 ET | 100 | 38.42 |
| 09:36 ET | 800 | 38.58 |
| 09:41 ET | 1622 | 38.59 |
| 09:45 ET | 300 | 38.52 |
| 09:48 ET | 1583 | 39.11 |
| 09:50 ET | 100 | 39.01 |
| 09:52 ET | 1659 | 38.85 |
| 09:54 ET | 300 | 38.72 |
| 09:56 ET | 100 | 38.7 |
| 09:57 ET | 862 | 38.785 |
| 09:59 ET | 100 | 38.965 |
| 10:01 ET | 1300 | 39.06 |
| 10:06 ET | 2200 | 38.945 |
| 10:10 ET | 1100 | 38.84 |
| 10:12 ET | 1119 | 38.91 |
| 10:15 ET | 400 | 39.015 |
| 10:17 ET | 1089 | 38.9824 |
| 10:19 ET | 500 | 39.15 |
| 10:21 ET | 400 | 39.155 |
| 10:24 ET | 470 | 39.04 |
| 10:26 ET | 500 | 39.02 |
| 10:30 ET | 400 | 39.15 |
| 10:32 ET | 400 | 39.195 |
| 10:33 ET | 619 | 39.19 |
| 10:35 ET | 403 | 39.16 |
| 10:37 ET | 600 | 39.23 |
| 10:39 ET | 200 | 39.295 |
| 10:42 ET | 1000 | 39.38 |
| 10:44 ET | 200 | 39.4 |
| 10:46 ET | 1097 | 39.32 |
| 10:48 ET | 400 | 39.33 |
| 10:50 ET | 2000 | 39.33 |
| 10:51 ET | 793 | 39.345 |
| 10:53 ET | 2102 | 39.06 |
| 10:55 ET | 100 | 39.06 |
| 10:57 ET | 800 | 39.11 |
| 11:02 ET | 700 | 39.26 |
| 11:04 ET | 1091 | 39.6 |
| 11:06 ET | 1217 | 39.6 |
| 11:08 ET | 1107 | 39.675 |
| 11:09 ET | 200 | 39.76 |
| 11:11 ET | 506 | 39.76 |
| 11:13 ET | 1000 | 39.745 |
| 11:15 ET | 816 | 39.69 |
| 11:18 ET | 600 | 39.63 |
| 11:22 ET | 700 | 39.75 |
| 11:24 ET | 700 | 39.82 |
| 11:26 ET | 1330 | 39.8 |
| 11:29 ET | 500 | 39.86 |
| 11:31 ET | 5148 | 39.46 |
| 11:33 ET | 1300 | 39.45 |
| 11:36 ET | 100 | 39.39 |
| 11:38 ET | 3201 | 39.39 |
| 11:40 ET | 300 | 39.15 |
| 11:42 ET | 1368 | 39.13 |
| 11:44 ET | 200 | 39.1 |
| 11:45 ET | 4460 | 39.01 |
| 11:47 ET | 353 | 39.01 |
| 11:49 ET | 300 | 38.955 |
| 11:51 ET | 982 | 38.91 |
| 11:54 ET | 300 | 38.98 |
| 11:56 ET | 100 | 38.98 |
| 11:58 ET | 600 | 38.79 |
| 12:00 ET | 100 | 38.85 |
| 12:02 ET | 802 | 38.74 |
| 12:03 ET | 100 | 38.79 |
| 12:05 ET | 800 | 38.78 |
| 12:07 ET | 1100 | 38.73 |
| 12:09 ET | 400 | 38.7 |
| 12:12 ET | 308 | 38.77 |
| 12:14 ET | 300 | 38.705 |
May 28, 2024
May 10, 2024
DJ Xenon Pharmaceuticals Is Maintained at Buy by Needham, from 6:12PM ET on Friday May 10, 2024 by Dow Jones
6:12PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Buy by Citigroup, from 5:48PM ET on Friday May 10, 2024 by Dow Jones
5:48PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush, from 9:30AM ET on Friday May 10, 2024 by Dow Jones
9:30AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.9B | -14.3x | --- |
Janux Therapeutics Inc | 2.8B | -44.9x | --- |
Apogee Therapeutics Inc | 2.7B | -22.2x | --- |
Biohaven Ltd | 3.1B | -5.1x | --- |
SpringWorks Therapeutics Inc | 3.1B | -7.8x | --- |
Dyne Therapeutics Inc | 3.1B | -8.0x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.22 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -14.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
